1
|
Saade S, Ghaoui N, Maamari M. Cutaneous sarcoidosis post platelet-rich plasma injections: A case report during the COVID pandemic. J Cosmet Dermatol 2024; 23:4-6. [PMID: 37365872 DOI: 10.1111/jocd.15901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Revised: 06/17/2023] [Accepted: 06/20/2023] [Indexed: 06/28/2023]
Affiliation(s)
- Serena Saade
- Department of Dermatology, American University of Beirut, Beirut, Lebanon
| | - Nohra Ghaoui
- Department of Dermatology, American University of Beirut, Beirut, Lebanon
| | | |
Collapse
|
2
|
Haller CN, Schnebelen A, Cadmus SD. Sarcoidal Tattoo Granuloma After COVID-19 Vaccine. JAAD Case Rep 2023; 48:S2352-5126(23)00217-5. [PMID: 38620113 PMCID: PMC10300053 DOI: 10.1016/j.jdcr.2023.06.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2022] [Revised: 05/30/2023] [Accepted: 06/12/2023] [Indexed: 04/17/2024] Open
Affiliation(s)
- Courtney N. Haller
- Division of Dermatology, Department of Internal Medicine, Dell Medical School, the University of Texas at Austin, Austin, Texas
| | | | - Simi D. Cadmus
- Division of Dermatology, Department of Internal Medicine, Dell Medical School, the University of Texas at Austin, Austin, Texas
| |
Collapse
|
3
|
Pokhriyal SC, Nabeel Pasha M, Khan A, Uwiringiyimana R, Idris H. Sarcoidosis Presenting as a Lung Mass in a Patient With COVID-19 Infection: A Case Report. Cureus 2023; 15:e39136. [PMID: 37332432 PMCID: PMC10275395 DOI: 10.7759/cureus.39136] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/17/2023] [Indexed: 06/20/2023] Open
Abstract
Coronavirus disease 2019 (COVID-19) is a viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which is known to be associated with immune dysregulation and can cause multiorgan dysfunction. Sarcoidosis is another disease associated with increased inflammatory responses due to immune dysregulation which can also affect multiple organs. Although sarcoidosis, like COVID-19 infection, can affect virtually any organ, the lungs are the most commonly affected organs. Sarcoidosis most commonly presents as lung nodules and bilateral hilar lymphadenopathy. Rarely, multiple granulomatous lesions can coalesce and manifest as lung masses, and these often mimic lung cancer. We present a case of a 64-year-old male who presented with shortness of breath and pneumonia-like symptoms for one week and a nasopharyngeal swab for SARS-CoV-2 was positive. Workup revealed a large 6.3×4.7 cm lung mass in the right upper lobe along with enlarged bilateral lymph nodes. A CT-guided lung biopsy was done which revealed non-caseating granulomas containing epithelioid cells. Other causes of granuloma like tuberculosis and fungal infections were ruled out. The patient was managed with low-dose steroids and a follow-up CT scan done after eight months revealed complete resolution of lung mass with minimal mediastinal lymphadenopathy. This is, as far as we are aware, the first case of COVID-19 infection manifesting as a lung mass that was ultimately diagnosed as sarcoidosis.
Collapse
Affiliation(s)
| | | | - Ahmad Khan
- Pulmonology, Interfaith Medical Center, New York City, USA
| | | | - Hadeeqa Idris
- Internal Medicine, Shifa International Hospital Islamabad, Islamabad, PAK
| |
Collapse
|
4
|
Cazzato G, Ambrogio F, Foti C, Capuzzolo M, Trilli I, Casatta N, Lupo C, Carrieri M, Daini D, Colagrande A, Maiorano E, Ingravallo G. Cutaneous Sarcoidosis-like Eruption Following Second Dose of Moderna mRNA-1273 Vaccine: Case or Relationship? Diagnostics (Basel) 2023; 13:diagnostics13071286. [PMID: 37046504 PMCID: PMC10093587 DOI: 10.3390/diagnostics13071286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Revised: 03/14/2023] [Accepted: 03/27/2023] [Indexed: 03/31/2023] Open
Abstract
Various adverse reactions to SARS-CoV-2 vaccines have been described since the first months of the vaccination campaign. In addition to more frequent reactions, rare reactions, such as sarcoidosis-like, rashes have been reported. We present a case of a 23-year-old woman with a rash on the chin and peribuccal region, which developed approximately 3 weeks after the administration of the second dose of the Moderna mRNA-1273 vaccine. We briefly discuss other reports in the literature.
Collapse
Affiliation(s)
- Gerardo Cazzato
- Section of Molecular Pathology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari “Aldo Moro”, 70124 Bari, Italy
- Correspondence: ; Tel.: +39-3405203641
| | - Francesca Ambrogio
- Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari “Aldo Moro”, 70124 Bari, Italy
| | - Caterina Foti
- Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari “Aldo Moro”, 70124 Bari, Italy
| | - Marialessandra Capuzzolo
- Section of Molecular Pathology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari “Aldo Moro”, 70124 Bari, Italy
| | - Irma Trilli
- Odontomatostologic Clinic, Department of Innovative Technologies in Medicine and Dentistry, University of Chieti “G. D’Annunzio”, 66100 Chieti, Italy
| | - Nadia Casatta
- Innovation Department, Diapath S.p.A., Via Savoldini n.71, 24057 Martinengo, Italy
| | - Carmelo Lupo
- Innovation Department, Diapath S.p.A., Via Savoldini n.71, 24057 Martinengo, Italy
| | | | - Daniele Daini
- Dermatology and Venereology, ASL Lecce, 73100 Lecce, Italy
| | - Anna Colagrande
- Section of Molecular Pathology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari “Aldo Moro”, 70124 Bari, Italy
| | - Eugenio Maiorano
- Section of Molecular Pathology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari “Aldo Moro”, 70124 Bari, Italy
| | - Giuseppe Ingravallo
- Section of Molecular Pathology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari “Aldo Moro”, 70124 Bari, Italy
| |
Collapse
|
5
|
Zhu CK, Nguyen A, Prosty C, Gabrielli S, Laboccetta V, Shand G, Mulé P, Netchiporouk E, Le M, Zhang X, Ke D, Baum S, Hakroush R, Greenberger S, Ben-Shoshan M. Safety of COVID-19 mRNA vaccination in children with chronic urticaria. THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. IN PRACTICE 2023; 11:1310-1313.e2. [PMID: 36621604 PMCID: PMC9812818 DOI: 10.1016/j.jaip.2022.12.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/13/2022] [Revised: 12/04/2022] [Accepted: 12/16/2022] [Indexed: 01/06/2023]
Affiliation(s)
- Catherine K Zhu
- Faculty of Medicine, McGill University, Montreal, QC, Canada.
| | - Alex Nguyen
- Faculty of Medicine, McGill University, Montreal, QC, Canada
| | - Connor Prosty
- Faculty of Medicine, McGill University, Montreal, QC, Canada
| | | | - Vera Laboccetta
- Centre for Outcome Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
| | - Greg Shand
- Centre for Outcome Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
| | - Pasquale Mulé
- Division of Pediatric Allergy and Clinical Immunology, Department of Pediatrics, McGill University Health Centre, Montreal, QC, Canada
| | - Elena Netchiporouk
- Division of Dermatology, McGill University Health Centre, Montreal, QC, Canada
| | - Michelle Le
- Division of Dermatology, McGill University Health Centre, Montreal, QC, Canada
| | - Xun Zhang
- Centre for Outcome Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
| | - Danbing Ke
- Centre for Outcome Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
| | - Sharon Baum
- Department of Dermatology, Chaim Sheba Medical Center, Tel-Aviv University, Sackler School of Medicine, Tel HaShomer, Israel
| | - Reman Hakroush
- Pediatric Dermatology Service, Department of Dermatology, Sheba Medical Center, Sackler School of Medicine, Ramat Gan, Israel
| | - Shoshana Greenberger
- Pediatric Dermatology Service, Department of Dermatology, Sheba Medical Center, Sackler School of Medicine, Ramat Gan, Israel
| | - Moshe Ben-Shoshan
- Division of Pediatric Allergy and Clinical Immunology, Department of Pediatrics, McGill University Health Centre, Montreal, QC, Canada
| |
Collapse
|
6
|
Song X, Shao F, Lan X. The Onset of Sarcoidosis After COVID-19 Vaccination Revealed by the 18 F-FDG PET. Clin Nucl Med 2022; 47:869-871. [PMID: 35867999 DOI: 10.1097/rlu.0000000000004352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
ABSTRACT Sarcoidosis is a heterogeneous multisystem disease characterized by noncaseating granulomas. We presented 18 F-FDG PET/CT findings of sarcoidosis in a previously healthy 43-year-old man who presented intermittent cough after the third dose of COVID-19 vaccination. 18 F-FDG PET/CT showed high uptake of one solitary nodule in the right middle lobe, mediastinal lymph nodes, bilateral hila, and multiple nodules under the right pleura, mimicking the malignancy. Nevertheless, the biopsy confirmed distinct noncaseating granulomas. This case emphasizes the onset of sarcoidosis revealed by 18 F-FDG PET/CT after COVID-19 vaccination.
Collapse
Affiliation(s)
- Xiangming Song
- From the Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hubei Key Laboratory of Molecular Imaging; and Key Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, China
| | | | | |
Collapse
|
7
|
Tozinameran. REACTIONS WEEKLY 2022. [PMCID: PMC9136754 DOI: 10.1007/s40278-022-16254-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
8
|
Effects of Vaccination against COVID-19 in Chronic Spontaneous and Inducible Urticaria (CSU/CIU) Patients: A Monocentric Study. J Clin Med 2022; 11:jcm11071822. [PMID: 35407429 PMCID: PMC8999670 DOI: 10.3390/jcm11071822] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2022] [Revised: 03/22/2022] [Accepted: 03/23/2022] [Indexed: 02/06/2023] Open
Abstract
Background: Patients affected by pre-existing chronic spontaneous/Inducible urticaria (CSU/CIU) still feel unsafe due to the potential risk of an Adverse Event Following Immunization (AEFI) and Cutaneous Adverse Reactions (CARs) of COVID-19 vaccines. The appropriate management in this field remains debated and evidence is still lacking. Methods: We considered 160 CSU/CIU patients in Omalizumab/antihistamine therapy who received two doses of Comirnaty/Moderna mRNA vaccines; 20 of them also received a booster dose. Urticaria Activity Score-7 (UAS7) was used to assess the severity of the disease. Demographics, medical history, AEFI and CARs outcome after vaccination were collected by administering a web-based questionnaire completed by phone interview. Results: In total, 147 patients did not show urticaria relapse (91.88%). Worsening cutaneous symptoms were experienced by 13 of our patients (8.12%). Exacerbation had a mean duration of 2 days and 11 h and mostly occurred after the first dose (69.23%). Systemic mild side effects were experienced by 9 patients (5.62%). No severe reactions were observed. Conclusions: Omalizumab can potentially prevent CARs and AEFI; however, major problems were registered during the 2-month stop period scheduled in the treatment. We suggest patients should not undergo vaccination during this period. CSU/CIU exacerbations appear to be transient and can be managed by antihistamines.
Collapse
|